By Dr Louise Emmett

Conference Papers

Holtkamp LHJ; Chakera A; Fung S; Stretch J; Saw R; Lee K; Gonzalez M; Thompson J; Emmett L; Nieweg OE, 2017, 'Staging F-18-FDG PET/CT Influences the Melanoma Treatment Plan in Patients with (Micro) Satellites or In-Transit Metastases', in ANNALS OF SURGICAL ONCOLOGY, SPRINGER, WA, Seattle, pp. S131 - S131, presented at 70th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO), WA, Seattle, 15 March 2017 - 18 March 2017

Roach P; Francis R; Emmett L; Hsiao E; Kneebone A; Hruby G; Eade T; Nguyen Q; Thompson B; McCarthy M; Tang C; Brenner P; Stricker P; Scott A, 2016, 'Australian multicentre evaluation of clinical management intent utilising Ga68-PSMA PET scans in patients with prostate cancer', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, SPAIN, Barcelona, pp. S165 - S165, presented at Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), SPAIN, Barcelona, 15 October 2016 - 19 October 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000391801600404&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ali SA; Emmett L; Wang J; Van Leeuwen P; Stark D; Morigi J; Stricker P, 2015, 'A comparison of the utility of F18 Choline and Ga68 PSMA PET/CT in identifying distant disease in high risk prostate cancer patients being considered for radical prostatectomy', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, GERMANY, Hamburg, pp. S380 - S380, presented at 28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), GERMANY, Hamburg, 10 October 2015 - 14 October 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000363013202257&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Morigi J; Stricker P; van Leeuwen P; Tang R; Ho B; Nguyen Q; Hickey A; Stark D; Young A; Fanti S; Tarlinton L; Emmett L, 2015, 'Prospective Comparison of the detection rate of 18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative intent therapy, being considered for targeted therapy', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, GERMANY, Hamburg, pp. S35 - S36, presented at 28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), GERMANY, Hamburg, 10 October 2015 - 14 October 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000363013201051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Zhang LF; Emmett L; Milner B; Belousova N; Clifford L; Havryk A; Stone E, 2015, 'Pilot introduction of the IASLC nodal classification system across EBUS-TBNA, CT and PET in staging of Non Small Cell Lung Cancer', in JOURNAL OF THORACIC ONCOLOGY, ELSEVIER SCIENCE INC, pp. S681 - S681, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000370365103281&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

van Leeuwen P; Stricker P; Morigi JJ; Quoc N; Kneebone A; Emmett L, 2015, 'Prospective comparison of the detection rate of F-18-Fluoromethylcholine and Ga-68-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Cairns, pp. 29 - 29, presented at 2nd Prostate Cancer World Congress (PCWC), AUSTRALIA, Cairns, 17 August 2015 - 21 August 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L, 2015, 'PET-PSMA IN PROSTATE CANCER: CHANGING OUR VIEW OF METASTATIC DISEASE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, AUSTRALIA, Sydney, pp. 30 - 30, presented at ANZUP Annual Scientific Meeting on Redefining Personalised Medicine, AUSTRALIA, Sydney, 12 July 2015 - 14 July 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000362808000028&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Slattery A; Le K; Emmett L; Young A, 2015, 'USING COMPUTER VISION FOR DETERMINING BONE INVOLVEMENT FOR LYMPHOMA PATIENTS WITH PET-CT IMAGES', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 2 - 2, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000353038000005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Clack M; Emmett L; Szeto E; Chan L; Ho B, 2014, 'ATTENUATION CORRECTION IN MYOCARDIAL PERFUSION IMAGING: A COMPARATIVE STUDY BETWEEN PRONE AND CTAC', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 19 - 19, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000334282000053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Al Cheikh E; Emmett L; Russo R, 2012, 'A COMPARATIVE EVALUATION OF PLANAR VS SPECT/CT IN THE ASSESSMENT OF SACROILIAC JOINT ACTIVITY', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 37 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307882100120&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sorensen N; Emmett L; Tow J, 2012, 'DETERMINING APPROPRIATE PROCESSING METHOD FOR SPECT DATA OF LYMPHOSCINTIGRAPHY SCANNING', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 6 - 6, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307882100018&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Droguett-Fuhrer N; Emmett L; Russo R; Al Cheikh E; Sorensen N, 2012, 'QUANTITATIVE ANALYSIS OF BLOOD POOL SPECT IMAGES IN THE EVALUATION OF THE SACROILIAC JOINTS', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 37 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307882100121&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Frater C; Mackey D; Emmett L; Van der Wall H, 2011, 'CALARA - Compassionate ALARA', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, pp. S448 - S448, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208619401785&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Frater C; Seccombe L; Chung S; Pearson M; Mackey D; Russo R; Emmett L, 2011, 'Glossopharyngeal breathing causes lung perfusion changes in Extreme Breath Hold Divers', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, pp. S458 - S459, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208619401833&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Al Cheikh E; Emmett L; Russo R; Mansberg R; Magee M; Yung G, 2011, 'DEVELOPMENT OF AN AGE AND SEX MATCHED NORMAL DATABASE FOR QUANTITATIVE SACROILIAC UPTAKE ON SPECT/CT Tc-99m-MDP BONE IMAGING', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 24 - 24, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000292514200075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Ng A; Sorensen N; Mansberg R; Kritharides L, 2011, 'Transient Ischaemic Dilation on Tc99m Adenosine Myocardial perfusion Imaging is not due to left ventricular cavity dilation or stunning. Comparison of echocardiography and myocardial perfusion imaging', in EUROPEAN HEART JOURNAL SUPPLEMENTS, OXFORD UNIV PRESS, NETHERLANDS, Amsterdam, pp. A59 - A59, presented at 10th International Conference of Non-Invasive Cardiovascular Imaging, NETHERLANDS, Amsterdam, 15 May 2011 - 18 May 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000291748800165&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Chung T; Connor D; Joseph J; Emmett L; Ma D; Kritharides L, 2006, 'Platelet activation, inflammation and cardiac dysfunction, and their relation to the extent of acute pulmonary embolism', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, SPAIN, Barcelona, pp. 295 - 295, presented at 28th Congress of the European-Society-of-Cardiology/World Congress of Cardiology, SPAIN, Barcelona, 02 September 2006 - 06 September 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000240668402012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Chung T; Emmett L; Kritharides L, 2006, 'Reduced tricuspid annular motion and right ventricular myocardial tissue velocities predict the extent and resolution of acute pulmonary embolism', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, SPAIN, Barcelona, pp. 616 - 616, presented at 28th Congress of the European-Society-of-Cardiology/World Congress of Cardiology, SPAIN, Barcelona, 02 September 2006 - 06 September 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000240668404188&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Husain M; Barolet A; Freeman M; Iwanochko RM, 2001, 'A reversible regional wall motion abnormality on single day exercise Tc-99m sestamibi gated SPECT perfusion: Imaging predicts a high grade angiographic stenosis.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, pp. 94P - 95P, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000168821900354&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Van der Wall H; Magee M; Emmett L; Bruce W, 2000, 'A new appraoch to the diagnosis of fat embolism.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, pp. 326P - 326P, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000089892401309&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Van der Wall H; Magee M; Magnussen J; Emmett L; Frater C; Murray P, 1999, 'A novel view for the scintigraphic assessment of the elbow.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, pp. 194P - 194P, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000080105800785&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Rivory LP; Clarke S; Bishop JF; O'Donnell A; Emmett L; Findlay M, 1998, 'Irinotecan (CPT-11): A preliminary investigation of the relationship between trough concentrations of the active metabolite, SN-38, and toxicity', in ANNALS OF ONCOLOGY, KLUWER ACADEMIC PUBL, pp. 59 - 59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000074749600194&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Posters

Meijer D; Vis A; Roberts M; Siriwardana A; Morton A; Yaxley J; Samaratunga H; Emmett L; van de Ven P; Heijmans M; Van der Poel H; Donswijk M; Boellaard T; Schoots I; Oprea-Lager D; Coughlin G; van Leeuwen P, 2022, 'MP51-03 DEVELOPMENT OF A NOVEL NOMOGRAM TO IDENTIFY CANDIDATES FOR EXTENDED PELVIC LYMPH-NODE DISSECTION IN PROSTATE CANCER USING MRI AND PSMA PET', Vol. 207, http://dx.doi.org/10.1097/ju.0000000000002626.03

Joshua AM; Stricker P; Epstein RJ; Ho B; Quoc N; Kent R; Willowson KP; Hofman M; Violet JA; Emmett L, 2017, 'Patterns of failure on Ga PSMA (GaPSMA) and F18 FDG (FDG) PET CT in a prospective phase 2 trial of Lu-177 DKFZ PSMA 617 (LuPSMA) in men with castrate resistant metastatic prostate cancer (mCRPC)', IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.2562

Conference Abstracts

Hotta M; Gafita A; Murthy V; Benz MR; Sonni I; Burger IA; Eiber M; Emmett L; Farolfi A; Fendler WP; Weber MM; Hofman MS; Hope TA; Kratochwil C; Czernin J; Calais J, 2023, 'PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [¹⁷⁷Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study', in Journal of Nuclear Medicine, Vol. 64, pp. 1024 - 1029, http://dx.doi.org/10.2967/jnumed.122.265242

Kwok M; McGeorge S; Jiang A; Emmett L; Pattison D; Thomas P; Yaxley J; Roberts M, 2022, 'Dual tracer PET using 68-Ga PSMA and 18-F FDG for staging prostate cancer: A systematic review', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Gold Coast, Vol. 129, pp. 143 - 143, presented at Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Gold Coast, 25 June 2022 - 28 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000808481200232&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ptasznik G; Moon D; Emmett L; Papa N; Kelly B; Roberts M; Hofman M; Thompson J; Murphy D; Stricker P, 2022, 'Is a biopsy necessary before offering a radical prostatectomy in all men? An analysis of the PI-RADS 4 & 5 lesions from the PRIMARY trial', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Gold Coast, Vol. 129, pp. 160 - 161, presented at Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Gold Coast, 25 June 2022 - 28 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000808481200262&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Kumar AR; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of Lu-177-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301433&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '⁶⁴Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3092 - 3092, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3092

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5027 - 5027, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5027

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of Lu-177-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301444&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, 'Cu-64-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2-metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680300985&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Menzies AM; Saw RPM; Lo SN; Gonzalez M; Ch'ng S; Nieweg OE; Shannon KF; Ferguson PM; Lee JHJ; Rizos H; Rawson RV; Stretch J; Thompson JF; Emmett L; Kapoor R; Spillane AJ; Scolyer RA; Long GV, 2022, 'Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 9580 - 9580, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.9580

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Ravi Kumar A; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5017 - 5017, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5017

Hotta M; Gafita A; Murthy V; Benz MR; Sonni I; Burger I; Eiber M; Emmett L; Farolfi A; Fendler WP; Hofman MS; Hope TA; Kratochwil C; Czernin J; Calais J, 2022, 'PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5043 - 5043, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5043

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Williams S; Martin AJ; Davis ID, 2022, 'TheraP: ¹⁷⁷Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5000 - 5000, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5000

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Williams S; Martin AJ; Davis ID, 2022, 'TheraP: Lu-177-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301419&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Schmidt-Hegemann N-S; Strouthos J; Farolfi A; Trapp C; Peeken J; Vogel MME; Vrachimis A; Belka C; Grosu A-L; Ceci F; Kroeze S; Guckenberger M; Henkenberens C; Emmett L; Zamboglou C; Wiegel T, 2022, 'Influence of PSMA PET-positive local recurrences on biochemical recurrence free survival after salvage radiotherapy in patients with recurrent or persistent prostate cancer-a multicenter retrospective study', in STRAHLENTHERAPIE UND ONKOLOGIE, SPRINGER HEIDELBERG, GERMANY, Stuttgart, Vol. 198, pp. S39 - S39, presented at 28th Congress of Deutsche-Gesellschaft-fur-Radioonkologie-e-V (DERGO), GERMANY, Stuttgart, 26 May 2022 - 28 May 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000791788000073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Eslick E; Counter W; Sharma S; Ayers M; Wong K; Nguyen A; Ho S; Pathmanandavel S; Hickey A; Emmett L, 2022, 'PSMA Screening phenotype allows personalisation of radiation safety recommendations.', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 52, pp. 29 - 30, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000794958100059&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Subramaniam S; Martin AJ; Zhang AY; Yip S; Crumbaker M; Rana N; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; Weickhardt AJ; Goh JC; Ng S; Voskoboynik M; McJannett MM; Stockler MR; Davis ID, 2022, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.TPS205

Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu SK; Joshua AM; Zhang AY; Francis RJ; Scott AM; Azad A; McJannett MM; Stockler MR; Williams S; Davis ID; Hofman MS, 2022, 'PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of Lu-177-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.010

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Niman R; Wilson P; Sharma S; Ayers M; Eu P; Stockler MR; Martin AJ; Joshua AM; Emmett L, 2022, 'Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1(77)LuPSMA-617 and NOX66 (LuPIN).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.166

Hotta M; Gafita A; Murthy V; Benz MR; Sonni I; Burger I; Eiber M; Emmett L; Farolfi A; Fendler WP; Hofman MS; Hope TA; Kratochwil C; Czernin J; Calais J, 2022, 'Predicting the outcome of mCPRC patients after Lu-177 PSMA therapy using semi-quantitative and visual criteria in baseline PSMA PET: An international multicenter retrospective study.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at ASCO Genitourinary Cancers Symposium, ELECTR NETWORK, 17 February 2022 - 19 February 2022, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.032

Meijer D; Vis AN; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; Van de Ven PM; Heijmans MW; Van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Oprea-Lager DE; Coughlin GD; Van Leeuwen PJ, 2022, 'Development of a novel nomogram to identify candidates for extended pelvic lymph-node dissection in prostate cancer using MRI and PSMA pet', in EUROPEAN UROLOGY, ELSEVIER, Vol. 81, pp. S981 - S982, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000812320401053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Doan PN; Counter W; Sheehan-Dare G; Papa N; Ho B; Lee J; Liu V; Thompson J; Agrawal S; Roberts M; Algharzo O; Buteau J; Hofman M; Moon D; Murphy D; Stricker P; Emmett L, 2022, 'Diagnostic accuracy, concordance and certainty with 68Ga-PSMA-11 PET/MRI fusion compared to mpMRI and 68Ga-PSMA-11 PET/CT alone for prostate cancer diagnosis: A PRIMARY trial sub-study', in EUROPEAN UROLOGY, ELSEVIER, Vol. 81, pp. S1103 - S1104, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000812320401137&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dimitriou F; Lo S; Tan AC; Emmett L; Kapoor R; Carlino M; Long GV; Menzies AM, 2021, 'FDG-PET to predict long-term outcome from anti-PD1 (PD1) therapy in metastatic melanoma', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S880 - S880, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1439

Sandhu SK; Joshua AM; Emmett L; Spain L; Horvath LG; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Kumar AR; Alipour R; Akhurst T; Kong G; Davis ID; Williams S; Hicks R; Hofman M, 2021, 'PRINCE: Interim analysis of the phase Ib study of Lu-177-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S626 - S627, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1090

Sheehan-Dare G; Lim E; Koo CM; Chan L; Lau B; Dear R; Ho B; Sharma S; Hickey A; Malaroda A; Smith I; Nguyen A; Parker M; Emmett L, 2021, 'Preliminary assessment of the diagnostic value of Cu-64-SAR-Bombesin PET-CT imaging for staging of ER+/PR+HER2-metastatic breast cancer disease: comparison with conventional imaging', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, Vol. 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713713600278&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hofman MS; Emmett L; Sandhu SK; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams S; Martin AJ; Davis ID, 2021, '177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.6

Emmett L; Subramaniam S; Zhang AY; Martin AJ; Yip S; Crumbaker M; Rana N; Ford K; Langford A; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; McJannett MM; Stockler MR; Davis ID, 2021, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS177

Back to profile page